Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma.

Benaniba L, Tessoulin B, Trudel S, Pellat-Deceunynck C, Amiot M, Minvielle S, Gourraud PA, de Visme S, Maisonneuve H, Lok A, Le Gouill S, Moreau P, Touzeau C.

BMC Cancer. 2019 Aug 29;19(1):855. doi: 10.1186/s12885-019-6080-8.

2.

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.

Papin A, Tessoulin B, Bellanger C, Moreau A, Le Bris Y, Maisonneuve H, Moreau P, Touzeau C, Amiot M, Pellat-Deceunynck C, Le Gouill S, Chiron D.

Leukemia. 2019 Oct;33(10):2442-2453. doi: 10.1038/s41375-019-0463-3. Epub 2019 Apr 2.

PMID:
30940906
3.

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells.

Tessoulin B, Descamps G, Dousset C, Amiot M, Pellat-Deceunynck C.

Front Oncol. 2019 Mar 6;9:128. doi: 10.3389/fonc.2019.00128. eCollection 2019.

4.

Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization.

Dubuisson A, Favreau C, Fourmaux E, Lareure S, Rodrigues-Saraiva R, Pellat-Deceunynck C, El Alaoui S, Micheau O.

Cell Death Dis. 2019 Feb 4;10(2):101. doi: 10.1038/s41419-019-1343-5.

5.

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker.

Tessoulin B, Papin A, Gomez-Bougie P, Bellanger C, Amiot M, Pellat-Deceunynck C, Chiron D.

Front Oncol. 2019 Jan 7;8:645. doi: 10.3389/fonc.2018.00645. eCollection 2018.

6.

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.

Tessoulin B, Moreau-Aubry A, Descamps G, Gomez-Bougie P, Maïga S, Gaignard A, Chiron D, Ménoret E, Le Gouill S, Moreau P, Amiot M, Pellat-Deceunynck C.

J Hematol Oncol. 2018 Dec 13;11(1):137. doi: 10.1186/s13045-018-0679-0.

7.

p53 regulates CD46 expression and measles virus infection in myeloma cells.

Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, Godon C, Le Bris Y, Vabret A, Bellanger C, Maillet L, Barillé-Nion S, Gregoire M, Fonteneau JF, Le Gouill S, Moreau P, Tangy F, Amiot M, Moreau-Aubry A, Pellat-Deceunynck C.

Blood Adv. 2018 Dec 11;2(23):3492-3505. doi: 10.1182/bloodadvances.2018025106.

8.

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.

Gomez-Bougie P, Maiga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez MS, Le Gouill S, Touzeau C, Moreau P, Pellat-Deceunynck C, Amiot M.

Blood. 2018 Dec 20;132(25):2656-2669. doi: 10.1182/blood-2018-03-836718. Epub 2018 Oct 11.

9.

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.

Gillardin PS, Descamps G, Maiga S, Tessoulin B, Djamai H, Lucani B, Chiron D, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C, Moreau-Aubry A.

Int J Mol Sci. 2017 Dec 23;19(1). pii: E40. doi: 10.3390/ijms19010040.

10.

Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

Lodé L, Ménard A, Flet L, Richebourg S, Loirat M, Eveillard M, Le Bris Y, Godon C, Theisen O, Gagez AL, Cartron G, Commes-Maerten T, Villemagne B, Luycx O, Godmer P, Pellat-Deceunynck C, Soussi T, Béné MC, Delaunay J, Peterlin P.

Haematologica. 2018 Apr;103(4):e143-e146. doi: 10.3324/haematol.2017.181404. Epub 2017 Dec 21. No abstract available.

11.

p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell.

Tessoulin B, Eveillard M, Lok A, Chiron D, Moreau P, Amiot M, Moreau-Aubry A, Le Gouill S, Pellat-Deceunynck C.

Blood Rev. 2017 Jul;31(4):251-259. doi: 10.1016/j.blre.2017.03.001. Epub 2017 Mar 4. Review.

PMID:
28284458
12.

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress.

Dufour F, Rattier T, Constantinescu AA, Zischler L, Morlé A, Ben Mabrouk H, Humblin E, Jacquemin G, Szegezdi E, Delacote F, Marrakchi N, Guichard G, Pellat-Deceunynck C, Vacher P, Legembre P, Garrido C, Micheau O.

Oncotarget. 2017 Feb 7;8(6):9974-9985. doi: 10.18632/oncotarget.14285.

13.

Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.

Gomez-Bougie P, Halliez M, Moreau P, Pellat-Deceunynck C, Amiot M.

Cancer Lett. 2016 Dec 28;383(2):204-211. doi: 10.1016/j.canlet.2016.09.030. Epub 2016 Sep 30.

PMID:
27697610
14.

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.

Hanf M, Chiron D, de Visme S, Touzeau C, Maisonneuve H, Jardel H, Pellat-Deceunynck C, Amiot M, le Gouill S.

BMC Cancer. 2016 Oct 14;16(1):802.

15.

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.

Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, Moreau A, Esbelin J, Trichet V, Chen-Kiang S, Moreau P, Touzeau C, Le Gouill S, Amiot M, Pellat-Deceunynck C.

Blood. 2016 Dec 15;128(24):2808-2818. Epub 2016 Oct 3.

PMID:
27697772
16.

The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation.

Gomez-Bougie P, Dousset C, Descamps G, Schnitzler A, Audiger L, Tessier A, Dubreuil D, Lebreton J, Pellat-Deceunynck C, Amiot M.

Br J Haematol. 2018 Jan;180(1):157-159. doi: 10.1111/bjh.14293. Epub 2016 Aug 14. No abstract available.

PMID:
27523575
17.

BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.

Dousset C, Maïga S, Gomez-Bougie P, Le Coq J, Touzeau C, Moreau P, Le Gouill S, Chiron D, Pellat-Deceunynck C, Moreau-Aubry A, Amiot M.

Br J Haematol. 2017 Nov;179(4):684-688. doi: 10.1111/bjh.14251. Epub 2016 Jul 29. No abstract available.

PMID:
27471002
18.

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.

Kervoëlen C, Ménoret E, Gomez-Bougie P, Bataille R, Godon C, Marionneau-Lambot S, Moreau P, Pellat-Deceunynck C, Amiot M.

Oncotarget. 2015 Sep 29;6(29):26922-34. doi: 10.18632/oncotarget.4616.

19.

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis.

Bustany S, Cahu J, Descamps G, Pellat-Deceunynck C, Sola B.

J Hematol Oncol. 2015 Apr 23;8:40. doi: 10.1186/s13045-015-0135-3.

20.

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.

Chiron D, Dousset C, Brosseau C, Touzeau C, Maïga S, Moreau P, Pellat-Deceunynck C, Le Gouill S, Amiot M.

Oncotarget. 2015 Apr 20;6(11):8750-9.

21.

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.

Maïga S, Brosseau C, Descamps G, Dousset C, Gomez-Bougie P, Chiron D, Ménoret E, Kervoelen C, Vié H, Cesbron A, Moreau-Aubry A, Amiot M, Pellat-Deceunynck C.

Cytometry A. 2015 Apr;87(4):285-8. doi: 10.1002/cyto.a.22643. Epub 2015 Feb 16. No abstract available.

22.

The origin of the plasma-cell heterogeneity.

Pellat-Deceunynck C, Defrance T.

Front Immunol. 2015 Jan 23;6:5. doi: 10.3389/fimmu.2015.00005. eCollection 2015. No abstract available.

23.

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.

Gomez-Bougie P, Halliez M, Maïga S, Godon C, Kervoëlen C, Pellat-Deceunynck C, Moreau P, Amiot M.

Cancer Biol Ther. 2015;16(1):60-5. doi: 10.4161/15384047.2014.986997.

24.

Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK.

Brosseau C, Dousset C, Touzeau C, Maïga S, Moreau P, Amiot M, Le Gouill S, Pellat-Deceunynck C.

Cell Death Dis. 2014 Aug 28;5:e1389. doi: 10.1038/cddis.2014.346.

25.

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.

Tessoulin B, Descamps G, Moreau P, Maïga S, Lodé L, Godon C, Marionneau-Lambot S, Oullier T, Le Gouill S, Amiot M, Pellat-Deceunynck C.

Blood. 2014 Sep 4;124(10):1626-36. doi: 10.1182/blood-2014-01-548800. Epub 2014 Jul 8.

PMID:
25006124
26.

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.

Surget S, Descamps G, Brosseau C, Normant V, Maïga S, Gomez-Bougie P, Gouy-Colin N, Godon C, Béné MC, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

BMC Cancer. 2014 Jun 14;14:437. doi: 10.1186/1471-2407-14-437.

27.

Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.

Surget S, Lemieux-Blanchard E, Maïga S, Descamps G, Le Gouill S, Moreau P, Amiot M, Pellat-Deceunynck C.

Leuk Lymphoma. 2014 Sep;55(9):2165-73. doi: 10.3109/10428194.2013.871277. Epub 2014 Feb 17.

PMID:
24308434
28.

Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease.

Lodé L, Moreau P, Ménard A, Godon C, Touzeau C, Amiot M, Le Gouill S, Béné MC, Pellat-Deceunynck C.

Blood Cancer J. 2013 Nov 22;3:e163. doi: 10.1038/bcj.2013.60. No abstract available.

29.

Cereblon expression in multiple myeloma: not ready for prime time.

Lodé L, Amiot M, Maiga S, Touzeau C, Menard A, Magrangeas F, Minvielle S, Pellat-Deceunynck C, Bene MC, Moreau P.

Br J Haematol. 2013 Oct;163(2):282-4. doi: 10.1111/bjh.12478. Epub 2013 Jul 17. No abstract available.

PMID:
23862718
30.

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.

Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, Maïga S, Béné MC, Moreau P, Pellat-Deceunynck C, Amiot M.

Leukemia. 2014 Jan;28(1):210-2. doi: 10.1038/leu.2013.216. Epub 2013 Jul 17. No abstract available.

31.

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.

Chiron D, Maïga S, Surget S, Descamps G, Gomez-Bougie P, Traore S, Robillard N, Moreau P, Le Gouill S, Bataille R, Amiot M, Pellat-Deceunynck C.

Blood Cancer J. 2013 Jun 7;3:e120. doi: 10.1038/bcj.2013.18.

32.

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.

Maïga S, Gomez-Bougie P, Bonnaud S, Gratas C, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M.

Br J Cancer. 2013 May 14;108(9):1801-6. doi: 10.1038/bjc.2013.186. Epub 2013 Apr 30.

33.

Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.

Surget S, Chiron D, Gomez-Bougie P, Descamps G, Ménoret E, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

Cancer Res. 2012 Sep 1;72(17):4562-73. doi: 10.1158/0008-5472.CAN-12-0487. Epub 2012 Jun 27.

34.

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction.

Descamps G, Gomez-Bougie P, Tamburini J, Green A, Bouscary D, Maïga S, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M.

Br J Cancer. 2012 May 8;106(10):1660-7. doi: 10.1038/bjc.2012.139. Epub 2012 Apr 17.

35.

Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.

Chiron D, Maïga S, Descamps G, Moreau P, Le Gouill S, Marionneau S, Ouiller T, Moreaux J, Klein B, Bataille R, Amiot M, Pellat-Deceunynck C.

Blood Cells Mol Dis. 2012 Apr 15;48(4):247-53. doi: 10.1016/j.bcmd.2012.01.006. Epub 2012 Feb 15.

PMID:
22341562
36.

A functional, new short isoform of death receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms.

Picarda G, Surget S, Guiho R, Téletchéa S, Berreur M, Tirode F, Pellat-Deceunynck C, Heymann D, Trichet V, Rédini F.

Mol Cancer Res. 2012 Mar;10(3):336-46. doi: 10.1158/1541-7786.MCR-11-0390. Epub 2012 Jan 18.

37.

Modulation of normal and malignant plasma cells function by toll-like receptors.

Jego G, Chiron D, Berthenet K, Pellat-Deceunynck C.

Front Biosci (Elite Ed). 2012 Jan 1;4:2289-301. Review.

PMID:
22202037
38.

The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients.

Chiron D, Surget S, Maïga S, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

Br J Haematol. 2012 Mar;156(5):679-83. doi: 10.1111/j.1365-2141.2011.08904.x. Epub 2011 Oct 11. No abstract available.

PMID:
21988294
39.

Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction.

Gomez-Bougie P, Ménoret E, Juin P, Dousset C, Pellat-Deceunynck C, Amiot M.

Biochem Biophys Res Commun. 2011 Sep 30;413(3):460-4. doi: 10.1016/j.bbrc.2011.08.118. Epub 2011 Sep 1.

PMID:
21907705
40.

ABT-737 is highly effective against molecular subgroups of multiple myeloma.

Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M.

Blood. 2011 Oct 6;118(14):3901-10. doi: 10.1182/blood-2010-11-317438. Epub 2011 Aug 11.

PMID:
21835956
41.

ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.

Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A, Moreau P, Pellat-Deceunynck C, Amiot M, Le Gouill S.

Clin Cancer Res. 2011 Sep 15;17(18):5973-81. doi: 10.1158/1078-0432.CCR-11-0955. Epub 2011 Aug 5.

42.

TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells.

Geffroy-Luseau A, Chiron D, Descamps G, Jégo G, Amiot M, Pellat-Deceunynck C.

Front Immunol. 2011 Dec 30;2:83. doi: 10.3389/fimmu.2011.00083. eCollection 2011.

43.

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M, Amiot M, Pellat-Deceunynck C.

Haematologica. 2011 Apr;96(4):574-82. doi: 10.3324/haematol.2010.033456. Epub 2010 Dec 20.

44.

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma.

Bodet L, Ménoret E, Descamps G, Pellat-Deceunynck C, Bataille R, Le Gouill S, Moreau P, Amiot M, Gomez-Bougie P.

Br J Cancer. 2010 Dec 7;103(12):1808-14. doi: 10.1038/sj.bjc.6605981. Epub 2010 Nov 9.

45.

Mcl-1(128-350) fragment induces apoptosis through direct interaction with Bax.

Ménoret E, Gomez-Bougie P, Surget S, Trichet V, Oliver L, Pellat-Deceunynck C, Amiot M.

FEBS Lett. 2010 Feb 5;584(3):487-92. doi: 10.1016/j.febslet.2009.11.094. Epub 2009 Dec 4.

46.

Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.

Chiron D, Pellat-Deceunynck C, Maillasson M, Bataille R, Jego G.

J Immunol. 2009 Oct 1;183(7):4371-7. doi: 10.4049/jimmunol.0901436. Epub 2009 Sep 4.

47.

TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production.

Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G.

J Immunol. 2009 Apr 1;182(7):4471-8. doi: 10.4049/jimmunol.0803113.

48.

IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop.

Ménoret E, Maïga S, Descamps G, Pellat-Deceunynck C, Fraslon C, Cappellano M, Moreau P, Bataille R, Amiot M.

J Immunol. 2008 Nov 15;181(10):6837-42.

49.

Toll-like receptors: lessons to learn from normal and malignant human B cells.

Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G.

Blood. 2008 Sep 15;112(6):2205-13. doi: 10.1182/blood-2008-02-140673. Epub 2008 Jun 30. Review.

50.

Osteoclasts support the survival of human plasma cells in vitro.

Geffroy-Luseau A, Jégo G, Bataille R, Campion L, Pellat-Deceunynck C.

Int Immunol. 2008 Jun;20(6):775-82. doi: 10.1093/intimm/dxn035. Epub 2008 Apr 8.

PMID:
18397910

Supplemental Content

Loading ...
Support Center